Drawing for INFIMED THERAPEUTICS, INC.

USPTO serial 76318058

INFIMED THERAPEUTICS, INC.

Reviewed by CopyMark Law Group

Status 601
Filing date
Status date
Registration date
—
Examiner
SOUDERS, MICHAEL J
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with INFIMED THERAPEUTICS, INC.?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

John a. Mizhir, Jr.

JOHN A MIZHIR JR FISH & RICHARDSON PC4350 LA JOLLA VILLAGE DR STE 500SAN DIEGO, CA 92122-6240UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceuticals, namely, drug delivery systems for the sustained release delivery of protein, small molecule and peptide drugsACTIVE—
042Research and development in the field of pharmaceuticals, namely, sustained release drug delivery systemsACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 4, 2002ABN1ABANDONMENT - EXPRESS MAILED—
Sep 9, 2002CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Sep 9, 2002MAILPAPER RECEIVED—
Jun 20, 2002CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 11, 2001CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 30, 2001DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance